Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10043
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBarlis, Peteren
dc.contributor.authorHorrigan, Mark C Gen
dc.contributor.authorChan, Robert Ken
dc.contributor.authorAjani, Andrew Een
dc.contributor.authorProimos, Georgeen
dc.contributor.authorSchumer, Wendy Aen
dc.contributor.authorvan Gaal, William Jen
dc.contributor.authorRowe, Michaelen
dc.contributor.authorEccleston, Daviden
dc.contributor.authorYan, Bryan B Pen
dc.contributor.authorMun Cheong, Yuen
dc.contributor.authorOliver, Les Een
dc.contributor.authorClark, David Jen
dc.date.accessioned2015-05-15T23:22:22Z
dc.date.available2015-05-15T23:22:22Z
dc.date.issued2005-10-12en
dc.identifier.citationCardiovascular Revascularization Medicine : Including Molecular Interventions; 6(4): 179-81en
dc.identifier.govdoc16326381en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10043en
dc.description.abstractIn-stent restenosis (ISR) remains a challenging problem in percutaneous coronary intervention and the optimal treatment strategy remains unclear. The aim of this study was to compare the 18 month clinical outcomes in patients receiving sirolimus-eluting stents (SES) with vascular brachytherapy (VBT) for the treatment of ISR. Twenty-five consecutive patients treated with VBT were compared with 29 patients who had SES deployment for ISR. Major adverse cardiac events (MACE) were defined as a combination of death from cardiac causes, nonfatal myocardial infarction, or repeat TVR. At 18 month follow-up, the MACE rate was significantly lower in the SES compared with the VBT group (14% vs 40%, P=.03). One patient in the VBT group developed late stent thrombosis (at 10 months) and died; there was no stent thrombosis in the SES group. This observational study, taken with other recent reports, offers further credence to the use of SES for ISR. The results of randomized comparisons with VBT are awaited with interest.en
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherBlood Vessel Prosthesis Implantation.instrumentationen
dc.subject.otherBrachytherapy.methodsen
dc.subject.otherCoated Materials, Biocompatibleen
dc.subject.otherCoronary Angiographyen
dc.subject.otherCoronary Restenosis.radiography.therapy.ultrasonographyen
dc.subject.otherDecision Makingen
dc.subject.otherEndosonographyen
dc.subject.otherFemaleen
dc.subject.otherFollow-Up Studiesen
dc.subject.otherHumansen
dc.subject.otherImmunosuppressive Agents.therapeutic useen
dc.subject.otherMaleen
dc.subject.otherRetrospective Studiesen
dc.subject.otherSirolimus.therapeutic useen
dc.subject.otherStentsen
dc.subject.otherTreatment Outcomeen
dc.titleWhat is the best contemporary treatment for in-stent restenosis?en
dc.typeJournal Articleen
dc.identifier.journaltitleCardiovascular revascularization medicine : including molecular interventionsen
dc.identifier.affiliationDepartment of Cardiology, Austin Hospital, Studley Road, PO Box 5555, Heidelberg, Victoria 3084, Australiaen
dc.identifier.doi10.1016/j.carrev.2005.10.001en
dc.description.pages179-81en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/16326381en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.